Current Update on Nanotechnology-Based Approaches in Ovarian Cancer Therapy

被引:14
作者
Bhardwaj, Boddapati Kalyani [1 ]
Thankachan, Sanu [1 ]
Magesh, Priyanila [1 ]
Venkatesh, Thejaswini [2 ]
Tsutsumi, Rie [3 ]
Suresh, Padmanaban S. [1 ]
机构
[1] Natl Inst Technol, Sch Biotechnol, Calicut 673601, Kerala, India
[2] Cent Univ Kerala, Dept Biochem & Mol Biol, Kasargod 671316, Kerala, India
[3] Tokushima Univ, Inst Biomed Sci, Dept Nutr & Metab, Grad Sch, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
关键词
Ovarian cancer; Dendrimers; Liposomes; Polymer nanoparticles; IRON-OXIDE NANOPARTICLES; IN-VITRO CYTOTOXICITY; DRUG-DELIVERY SYSTEM; TARGETED DELIVERY; POLYMERIC MICELLES; MULTIDRUG-RESISTANCE; LIPOSOME INJECTION; PANCREATIC-CANCER; SIGNALING PATHWAY; PACLITAXEL;
D O I
10.1007/s43032-022-00968-1
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovarian cancer is one of the leading causes of cancer-related deaths among women. The drawbacks of conventional therapeutic strategies encourage researchers to look for alternative strategies, including nanotechnology. Nanotechnology is one of the upcoming domains of science that is rechanneled towards targeted cancer therapy and diagnosis. Nanocarriers such as dendrimers, liposomes, polymer micelles, and polymer nanoparticles present distinct surface characteristics in morphology, surface chemistry, and mode of action that help differentiate normal and malignant cells, which paves the way for target-specific drug delivery. Similarly, nanoparticles have been strategically utilized as efficacious vehicles to deliver drugs that alter the epigenetic modifications in epigenetic therapy. Some studies suggest that the use of specialized target-modified nanoparticles in siRNA-based nanotherapy prevents internalization and improves the antitumor activity of siRNA by ensuring unrestrained entry of siRNA into the tumor vasculature and efficient intracellular delivery of siRNA. Moreover, research findings highlight the significance of utilizing nanoparticles as depots for photosensitive drugs in photodynamic therapy. The applicability of nanoparticles is further extended to medical imaging. They serve as contrast agents in combination with conventional imaging modalities such as MRI, CT, and fluorescence-based imaging to produce vivid and enhanced images of tumors. Therefore, this review aims to explore and delve deeper into the advent of various nanotechnology-based therapeutic and imaging techniques that provide non-invasive and effective means to tackle ovarian cancers.
引用
收藏
页码:335 / 349
页数:15
相关论文
共 105 条
[1]   AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth [J].
Altomare, DA ;
Wang, HQ ;
Skele, KL ;
De Rienzo, A ;
Klein-Szanto, AJ ;
Godwin, AK ;
Testa, JR .
ONCOGENE, 2004, 23 (34) :5853-5857
[2]  
[Anonymous], 2021, OV CANC
[3]   Chitosan Coated Polylactic Acid Nanoparticle-Mediated Combinatorial Delivery of Cisplatin and siRNA/Plasmid DNA Chemosensitizes Cisplatin-Resistant Human Ovarian Cancer Cells [J].
Babu, Anish ;
Wang, Qi ;
Muralidharan, Ranganayaki ;
Shanker, Manish ;
Munshi, Anupama ;
Ramesh, Rajagopal .
MOLECULAR PHARMACEUTICS, 2014, 11 (08) :2720-2733
[4]   Core-shell poly-methyl methacrylate nanoparticles covalently functionalized with a non-symmetric porphyrin for anticancer photodynamic therapy [J].
Ballestri, Marco ;
Caruso, Enrico ;
Guerrini, Andrea ;
Ferroni, Claudia ;
Banfi, Stefano ;
Gariboldi, Marzia ;
Monti, Elena ;
Sotgiu, Giovanna ;
Varchi, Greta .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 2018, 186 :169-177
[5]   Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy [J].
Bertucci, Alessandro ;
Kim, Kang-Hoon ;
Kang, Jinyoung ;
Zuidema, Jonathan M. ;
Lee, Seo Hyeon ;
Kwon, Ester J. ;
Kim, Dokyoung ;
Howell, Stephen B. ;
Ricci, Francesco ;
Ruoslahti, Erkki ;
Jang, Hyeung-Jin ;
Sailor, Michael J. .
ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (27) :23926-23937
[6]   Molybdenum cluster loaded PLGA nanoparticles as efficient tools against epithelial ovarian cancer [J].
Brandhonneur, N. ;
Boucaud, Y. ;
Verger, A. ;
Dumait, N. ;
Molard, Y. ;
Cordier, S. ;
Dollo, G. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 592
[7]   CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer [J].
Byeon, Yeongseon ;
Lee, Jeong-Won ;
Choi, Whan Soo ;
Won, Ji Eun ;
Kim, Ga Hee ;
Kim, Min Gi ;
Wi, Tae In ;
Lee, Jae Myeong ;
Kang, Tae Heung ;
Jung, In Duk ;
Cho, Young-Jae ;
Ahn, Hyung Jun ;
Shin, Byung Cheol ;
Lee, Young Joo ;
Sood, Anil K. ;
Han, Hee Dong ;
Park, Yeong-Min .
CANCER RESEARCH, 2018, 78 (21) :6247-6256
[8]   A mechanism for modulation of cellular responses to VEGF: Activation of the integrins [J].
Byzova, TV ;
Goldman, CK ;
Pampori, N ;
Thomas, KA ;
Bett, A ;
Shattil, SJ ;
Plow, EF .
MOLECULAR CELL, 2000, 6 (04) :851-860
[9]   Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy [J].
Chari, RVJ .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 31 (1-2) :89-104
[10]   Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers [J].
Chen, Feng-qian ;
Zhang, Jin-ming ;
Fang, Xie-fan ;
Yu, Hua ;
Liu, Yu-ling ;
Li, Hui ;
Wang, Yi-tao ;
Chen, Mei-wan .
ACTA PHARMACOLOGICA SINICA, 2017, 38 (06) :859-873